Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Quetiapine works by attaching to specific sites in the brain that respond to dopamine and serotonin — two chemical messengers involved in mood, thought patterns, and perception. It blocks more serotonin receptors than dopamine receptors, which is thought to explain why it can reduce symptoms of psychosis while causing fewer movement problems than older antipsychotic medications. The body also converts quetiapine into an active breakdown product called norquetiapine, which continues to work in a similar way.
Doctors prescribe quetiapine to treat schizophrenia, acute episodes of mania, and depressive episodes in people with bipolar disorder. It's also used long-term to help prevent manic, depressive, or mixed episodes from returning in bipolar I disorder, either on its own or alongside lithium or sodium valproate.
Quetiapine leaves the body relatively quickly — the parent medication has a half-life of about seven hours, and norquetiapine clears over nine to twelve hours. The liver enzyme CYP3A4 does most of the work breaking down both substances, with two other enzymes playing smaller roles. This matters because other medications that speed up or slow down CYP3A4 can affect how much quetiapine stays in your family member's system.
Common side effects include headache, drowsiness, dizziness, constipation, and dry mouth. These often settle as the body adjusts, but mention them to the prescribing doctor if they persist or cause discomfort.
Serious side effects are less common but require immediate medical attention. These include neuroleptic malignant syndrome — a rare reaction involving high fever, muscle rigidity, and confusion — as well as a severe drop in white blood cells, involuntary movements that may become permanent, seizures, and muscle breakdown. If your family member develops a high fever, becomes unusually stiff, has new uncontrolled movements, or shows signs of severe illness while taking quetiapine, contact emergency services or the prescribing doctor straight away. Quetiapine should not be used by anyone with a known allergy to any ingredient in the product.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationAcute mania Clinical criteria: The condition must be associated with bipolar I disorder, AND The treatment must be as monotherapy, AND The treatment must be limited to up to 6 months per episode.
Bipolar I disorder Clinical criteria: The treatment must be maintenance therapy.
“Quetiapine and norquetiapine exhibit affinity for brain serotonin (5HT2) and dopamine D1 and D2 receptors; this combination of receptor antagonism with a higher selectivity for 5HT2 relative to D2 receptors is believed to contribute to the clinical antipsychotic properties and low extrapyramidal side effects (EPS) liability of quetiapine compared to typical antipsychotics.”
“The elimination half-lives of quetiapine and norquetiapine are approximately 7 and 12 hours respectively.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Quetiapine is a second-generation antipsychotic with antagonist activity at serotonin 5HT2 and dopamine D1 and D2 receptors. The higher selectivity for 5HT2 relative to D2 receptors is thought to account for its antipsychotic efficacy and lower liability for extrapyramidal side effects compared with typical antipsychotics. Quetiapine holds TGA approval for the treatment of schizophrenia, acute mania associated with bipolar I disorder (as monotherapy or in combination with lithium or sodium valproate), depressive episodes associated with bipolar disorder, and maintenance treatment of bipolar I disorder for the prevention of relapse or recurrence of manic, depressive or mixed episodes.
The parent compound has an elimination half-life of approximately 7 hours; the active metabolite norquetiapine has a half-life of 9–12 hours. Quetiapine is metabolised primarily via CYP3A4, which is also the principal enzyme responsible for formation and elimination of norquetiapine; CYP2D6 and CYP2C9 contribute to quetiapine metabolism. Commonly reported adverse effects include somnolence, dizziness, headache, dry mouth and constipation. Serious adverse effects include neuroleptic malignant syndrome, agranulocytosis, tardive dyskinesia, seizure and rhabdomyolysis. Quetiapine is contraindicated in patients hypersensitive to any component of the product.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“In vitro investigations established that CYP3A4 is likely to be the primary enzyme responsible for cytochrome P450 mediated metabolism of quetiapine. Norquetiapine is primarily formed and eliminated via CYP3A4. CYP2D6 and CYP2C9 are also involved in quetiapine metabolism.”